392 related articles for article (PubMed ID: 22738299)
1. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
[TBL] [Abstract][Full Text] [Related]
2. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects.
Vanis L; Hausken T; Gentilcore D; Rigda RS; Rayner CK; Feinle-Bisset C; Horowitz M; Jones KL
Br J Nutr; 2011 Jun; 105(11):1644-51. PubMed ID: 21294929
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
[TBL] [Abstract][Full Text] [Related]
5. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
6. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
[TBL] [Abstract][Full Text] [Related]
7. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
8. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
9. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes.
Gentilcore D; Chaikomin R; Jones KL; Russo A; Feinle-Bisset C; Wishart JM; Rayner CK; Horowitz M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2062-7. PubMed ID: 16537685
[TBL] [Abstract][Full Text] [Related]
10. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
11. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
12. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
Kuo P; Stevens JE; Russo A; Maddox A; Wishart JM; Jones KL; Greville H; Hetzel D; Chapman I; Horowitz M; Rayner CK
J Clin Endocrinol Metab; 2011 May; 96(5):E851-5. PubMed ID: 21389144
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
14. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
15. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
16. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
[TBL] [Abstract][Full Text] [Related]
17. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.
Idorn T; Knop FK; Jørgensen MB; Christensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2457-66. PubMed ID: 24712563
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
20. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.
Wu T; Bound MJ; Zhao BR; Standfield SD; Bellon M; Jones KL; Horowitz M; Rayner CK
Diabetes Care; 2013 Jul; 36(7):1913-8. PubMed ID: 23359361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]